Research company Oncopeptides announces that three abstracts describing preclinical and translational data on the application of next-generation alkylating peptide-drug conjugates in glioblastoma have been accepted for poster presentation at the 2026 congress of the European Association of Neuro-Oncology, EANO, taking place in Rome from 24 to 27 September.
“This constitutes the first major scientific presentations on glioblastoma based on Oncopeptides’ data, marking an important step into a new indication with a significant unmet medical need,” the company writes in a press release.
